[Anticoagulation after venous thrombosis caused by type-II HIT syndrome].
Janssens
U
U
Medizinische Klinik I, Universitätsklinikum, Rheinisch-Westfälischen Technischen Hochschule, Aachen. UJAN@pcserver.mk1.rwth-aachen.de
D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D003374:Coumarins / Q000627:therapeutic use; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000009:adverse effects*; D024764:Hirudin Therapy; D006629:Hirudins / Q000031:analogs & derivatives; D006801:Humans; D008875:Middle Aged; D010644:Phenprocoumon / Q000627:therapeutic use; D011655:Pulmonary Embolism / Q000188:drug therapy; D011994:Recombinant Proteins / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000150:complications; D013924:Thrombophlebitis / Q000188:drug therapy* / Q000209:etiology; D013997:Time Factors
D000925:Anticoagulants; D003374:Coumarins; D005343:Fibrinolytic Agents; D006629:Hirudins; D011994:Recombinant Proteins; D006493:Heparin; D010644:Phenprocoumon; C083544:lepirudin
Antikoagulation nach Venenthrombose durch HIT-Syndrom Typ II.